Neuralgia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment (Drug-Based, Surgery), By Indication (Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia, Trigeminal Neuralgia), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 1.34 Billion
CAGR (2026-2031)	8.86%
Fastest Growing Segment	Online Pharmacies
Largest Market	North America
Market Size (2031)	USD 2.23 Billion

Market Overview

The Global Neuralgia Treatment Market will grow from USD 1.34 Billion in 2025 to USD 2.23 Billion by 2031 at a 8.86% CAGR. The Global Neuralgia Treatment Market encompasses a range of pharmacological and interventional therapies designed to manage neuropathic pain, a chronic condition characterized by nerve damage resulting in sharp, shooting, or burning sensations. The primary drivers fueling market expansion include the rapidly aging global population, who are disproportionately susceptible to postherpetic neuralgia, and the escalating prevalence of chronic metabolic disorders such as diabetes which frequently precipitate peripheral neuropathy. These fundamental demand factors are distinct from evolving market trends, such as the preference for non-opioid analgesics, as they represent the core physiological burden necessitating therapeutic intervention.

However, market expansion is impeded by the significant challenge of adverse drug effects and diagnostic complexities which often lead to patient non-compliance or untreated cases. High rates of underdiagnosis remain a critical barrier to effective care delivery and market penetration. According to the American Diabetes Association, in 2025, distal symmetric polyneuropathy may be present in at least 10 percent to 15 percent of newly diagnosed patients with type 2 diabetes. This data underscores the immense volume of patients requiring early neuropathic management who often go undetected, thereby limiting the addressable market size for available treatments.

Key Market Drivers

The rising prevalence of diabetes and diabetic neuropathy acts as a foundational driver for the Global Neuralgia Treatment Market. Chronic hyperglycemia systematically damages peripheral nerves, creating a massive reservoir of patients suffering from painful diabetic neuropathy (PDN) who require long-term analgesic or anticonvulsant therapy. This demographic expansion necessitates a sustained increase in the production and prescription of neuropathic pain management solutions. According to the International Diabetes Federation, December 2025, in the 'IDF Diabetes Atlas 11th Edition', approximately 589 million adults were living with diabetes globally in 2024. This staggering prevalence ensures that diabetic neuropathy remains the dominant clinical indication propelling market demand, as a significant proportion of these individuals will eventually require therapeutic intervention for nerve damage.

Simultaneously, advancements in pharmacological and surgical pain management interventions are aggressively expanding the market's scope. Manufacturers are increasingly prioritizing the development of non-opioid pharmaceuticals and sophisticated neuromodulation devices to address the limitations of conventional treatments. This shift is characterized by substantial strategic investments and regulatory milestones that enhance treatment efficacy and patient safety. For instance, according to Boston Scientific, October 2025, in a corporate press release, the company announced the acquisition of Nalu Medical for approximately $533 million to integrate advanced peripheral nerve stimulation technologies into its portfolio. Additionally, regulatory approvals for next-generation systems are accelerating adoption rates. According to Saluda Medical, in 2025, the U.S. FDA granted approval for the EVA programming platform, an automated system designed to optimize spinal cord stimulation outcomes, illustrating the rapid technological maturation within the interventional segment.

Download Free Sample Report

Key Market Challenges

Diagnostic complexities constitute a substantial impediment to the growth of the global neuralgia treatment market. Neuropathic pain is frequently subjective and difficult to identify using standard clinical tests, particularly during the early onset of symptoms. Because these sensations can mimic other medical conditions, healthcare providers often face difficulties in accurately pinpointing the specific nerve damage. This diagnostic ambiguity frequently results in delayed or missed identifications of the condition. When patients do not receive a definitive diagnosis, they cannot be prescribed the appropriate pharmacological or interventional therapies, effectively preventing them from entering the consumer base for these treatments.

This high rate of underdiagnosis directly restricts the total addressable market size. Without a confirmed diagnosis, patients do not generate demand for prescription analgesics or neurostimulation devices, leaving a gap between actual disease prevalence and treatment revenue. According to the Foundation for Peripheral Neuropathy, in 2025, approximately 30 million people in the United States were estimated to suffer from some form of peripheral neuropathy, yet a significant portion remained untreated due to diagnostic challenges. This discrepancy highlights a considerable volume of potential market value that remains inaccessible due to current clinical limitations.

Key Market Trends

The Development of Selective Voltage-Gated Sodium Channel Blockers represents a transformative shift in pharmacological interventions, moving beyond broad-spectrum analgesics to precision targeting of peripheral pain signals. This trend focuses on inhibiting specific ion channels, such as NaV1.8, which are highly expressed in nociceptors and play a critical role in the transmission of neuropathic pain without the central nervous system side effects associated with opioids. The validation of this mechanism has accelerated dramatically, establishing a new class of therapeutics that directly addresses the physiological root of neuralgia. According to Vertex Pharmaceuticals, January 2025, in the 'Vertex Announces FDA Approval of JOURNAVX' press release, the company received U.S. FDA approval for suzetrigine, a highly selective NaV1.8 pain signal inhibitor, marking the first new class of medicine for acute pain in over two decades and paving the way for its advanced Phase 3 development in diabetic peripheral neuropathy.

Simultaneously, Advancements in Next-Generation Neuromodulation Devices are redefining the interventional landscape through the deployment of closed-loop systems that adapt to patient physiology in real-time. Unlike traditional fixed-output stimulators, these novel devices utilize sophisticated sensing technology to detect Evoked Compound Action Potentials (ECAPs), allowing the system to automatically adjust stimulation levels based on the patient's spinal cord activity and body movements. This capability maintains optimal therapeutic efficacy while preventing the overstimulation often caused by daily activities like coughing or bending. A pivotal expansion in this segment occurred when, according to Medtronic, March 2025, in the 'Medtronic at the forefront of new era for spinal cord stimulation technology' press release, the company announced the availability of the Inceptiv closed-loop rechargeable spinal cord stimulator, which senses biological signals 50 times per second to deliver consistent therapy for chronic pain patients.

Segmental Insights

Online pharmacies represent the fastest-growing segment in the global neuralgia treatment market due to the increasing adoption of digital healthcare solutions. This growth is largely fueled by the convenience offered to patients with severe nerve pain, who frequently encounter mobility challenges that complicate visits to physical locations. Additionally, the formalization of electronic prescription standards by health regulatory bodies has significantly improved the legitimacy and safety of purchasing medication remotely. Consequently, patients are increasingly favoring these platforms for their cost-effectiveness, privacy, and direct home delivery, marking a distinct transition away from traditional retail channels.

Regional Insights

North America holds a dominant position in the Global Neuralgia Treatment Market due to its established healthcare infrastructure and the high prevalence of associated conditions such as diabetic neuropathy. The region benefits from a favorable regulatory environment, where the US Food and Drug Administration actively facilitates the approval of new therapeutic options. Furthermore, the presence of major pharmaceutical companies combined with comprehensive reimbursement frameworks ensures broad patient access to necessary treatments. This strong commercial ecosystem and continuous investment in clinical research sustain North America's leadership in the global sector.

Recent Developments

• In August 2025, NeuroOne Medical Technologies received FDA 510(k) clearance to market its OneRF Trigeminal Nerve Ablation System for the treatment of trigeminal neuralgia. This clearance marked the company's strategic expansion into the chronic pain market with a device specifically designed to create radiofrequency lesions to interrupt pain signals in the trigeminal nerve. The system employs a proprietary multi-contact probe that allows for temperature-controlled ablation, offering a new minimally invasive surgical option for patients suffering from this debilitating facial neuralgia condition.
• In January 2025, Nalu Medical announced that it received FDA clearance for expanded labeling of its Nalu Neurostimulation System, specifically for whole-body MRI-conditional use in Peripheral Nerve Stimulation (PNS). This regulatory milestone allows the company to market its implantable device to a broader population of patients suffering from severe chronic intractable pain of peripheral nerve origin, a key segment of the neuralgia market. The expanded labeling addresses a significant limitation for patients who require regular diagnostic imaging, thereby enhancing the commercial viability and patient accessibility of this minimally invasive neuralgia treatment.
• In October 2024, Vertex Pharmaceuticals initiated its Phase 3 pivotal program for suzetrigine (VX-548) specifically in patients with painful diabetic peripheral neuropathy (DPN). Following positive Phase 2 results and an End-of-Phase 2 meeting with the FDA, the company moved forward with evaluating this oral, selective NaV1.8 pain signal inhibitor for this specific neuralgia indication. The FDA also granted suzetrigine Breakthrough Therapy designation for the treatment of pain associated with DPN, highlighting the urgent need for new therapeutic options in the global neuralgia treatment market beyond traditional opioids and anticonvulsants.
• In February 2024, Latigo Biotherapeutics emerged from stealth mode with a significant capital raise of $135 million in Series A financing to advance its pipeline of non-opioid pain medicines. The company’s lead program, LTG-001, is an oral, selective NaV1.8 inhibitor intended to treat acute and chronic pain conditions, including neuropathic pain which encompasses various forms of neuralgia. This funding was led by Westlake Village BioPartners and aims to accelerate the clinical development of LTG-001, which targets the same pain-signaling sodium channel as other major breakthrough therapies in the neuralgia treatment market.

Key Market Players

• GSK PLC
• Pfizer Inc
• Novartis AG
• Biogen Inc
• Cadila Pharmaceuticals Ltd
• Lundbeck Pharmaceuticals Ltd
• Zydus Group
• Eli Lily and Company
• Allergan Inc.
• Baxter International Inc.

By Treatment	By Indication	By Distribution Channel	By Region
Drug-Based Surgery	Diabetic Neuropathy Intercostal Neuralgia Occipital Neuralgia Peripheral Neuralgia Postherpetic Neuralgia Trigeminal Neuralgia	Hospital Pharmacies Online Pharmacies Retail Pharmacies	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neuralgia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Neuralgia Treatment Market, By Treatment:

• Drug-Based
• Surgery

• Neuralgia Treatment Market, By Indication:

• Diabetic Neuropathy
• Intercostal Neuralgia
• Occipital Neuralgia
• Peripheral Neuralgia
• Postherpetic Neuralgia
• Trigeminal Neuralgia

• Neuralgia Treatment Market, By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies

• Neuralgia Treatment Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE